Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Purchased by Entropy Technologies LP

Key Points

• Entropy Technologies LP increased its ownership in Dynavax Technologies by 111.5% during the first quarter, acquiring over 54,000 additional shares, bringing its total shares to 102,834.
• Dynavax Technologies reported an earnings per share (EPS) of $0.14 for the last quarter, exceeding estimates of $0.12, with revenue of $95.44 million compared to anticipated revenue of $87.55 million.
• Analysts have mixed ratings for Dynavax, with one report upgrading it to a "buy" while another lowered the target price to $10, resulting in an average rating of "Moderate Buy" with a consensus target of $24.33.

Entropy Technologies LP raised its position in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 111.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,834 shares of the biopharmaceutical company's stock after purchasing an additional 54,213 shares during the period. Entropy Technologies LP owned 0.09% of Dynavax Technologies worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. O Shaughnessy Asset Management LLC acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $131,000. Franklin Resources Inc. boosted its stake in Dynavax Technologies by 5.2% during the 4th quarter. Franklin Resources Inc. now owns 86,675 shares of the biopharmaceutical company's stock worth $1,107,000 after purchasing an additional 4,260 shares during the period. Envestnet Asset Management Inc. boosted its stake in Dynavax Technologies by 20.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company's stock worth $206,000 after purchasing an additional 2,796 shares during the period. Russell Investments Group Ltd. boosted its stake in Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares during the period. Finally, Martingale Asset Management L P acquired a new stake in Dynavax Technologies during the 4th quarter worth $152,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVAX has been the subject of a number of recent research reports. JMP Securities increased their price target on shares of Dynavax Technologies from $31.00 to $32.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $24.33.

Dynavax Technologies Trading Up 1.6%

Shares of DVAX traded up $0.17 during mid-day trading on Friday, hitting $10.79. The company had a trading volume of 1,019,772 shares, compared to its average volume of 1,373,379. The stock has a market cap of $1.27 billion, a PE ratio of -23.46 and a beta of 1.09. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45. Dynavax Technologies Corporation has a 1-year low of $9.22 and a 1-year high of $14.63. The business's 50-day simple moving average is $10.57 and its 200-day simple moving average is $11.49.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The firm had revenue of $95.44 million for the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Sell-side analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.